Core Viewpoint - Huaxi Biological Technology Co., Ltd. reported a significant transformation from scale expansion to quality improvement in its operations, achieving notable profit growth despite a decline in revenue [1][4]. Financial Performance - The company achieved total revenue of 4.217 billion yuan in 2025, a year-on-year decrease of 21.49% [2]. - Net profit attributable to shareholders reached 291 million yuan, an increase of 67.03% compared to the previous year [2]. - The net profit after deducting non-recurring gains and losses was 188 million yuan, reflecting a 75.28% year-on-year growth [2]. - The weighted average return on equity was 4.17%, up 1.62 percentage points from the previous year [2]. Business Strategy - The decline in revenue was attributed to systematic structural optimization in skin science and nutrition science innovation, focusing on core brands and product categories [2][3]. - The company is shifting its marketing strategy from scale-oriented to efficiency-oriented, enhancing brand communication and resource allocation [2][3]. Operational Efficiency - The company streamlined overlapping departments and optimized its organizational structure, resulting in a management expense reduction of over 10% year-on-year [3]. - Sales expenses decreased by over 30% in 2025, contributing to improved profitability despite revenue pressure [3]. Research and Innovation - The company is focusing on research in glycoscience and cell biology, enhancing its capabilities in the industrialization of bioactive materials and regenerative materials [3]. - Digitalization and AI technologies are being integrated into production, supply chain management, and internal operations to improve overall operational efficiency [3]. Future Outlook - The company aims to continue its transformation towards quality growth, leveraging synthetic biology and industrialization capabilities to enhance core competencies and sustainable development [4].